Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2020 Nov 2

PMID 33132699

Citations 7

Authors

Ruben A G van Eerden

Ron H J Mathijssen

Stijn L W Koolen

Affiliations

Soon will be listed here.

Abstract

Conventional taxanes are used as cornerstone of the chemotherapeutical treatment for a variety of malignancies. Nevertheless, a large proportion of patients do not benefit from their treatment while they do suffer from severe adverse events related to the solvent or to the active compound. Cremophor EL and polysorbate 80 free formulations, conjugates, oral formulations and different types of drug delivery systems are some examples of the several attempts to improve the treatment with taxanes. In this review article, we discuss recent clinical developments of nanomediated drug delivery systems of taxanes for the treatment of cancer. Targeting mechanisms of drug delivery systems and characteristics of the most commonly used taxane-containing drug delivery systems in the clinical setting will be discussed in this review.

Citing Articles

Natural Taxanes: From Plant Composition to Human Pharmacology and Toxicity.

Niznansky L, Osinova D, Kuruc R, Hengerics Szabo A, Szoradova A, Masar M Int J Mol Sci. 2022; 23(24).

PMID: 36555256 PMC: 9779243. DOI: 10.3390/ijms232415619.

Polysaccharide dextran-based conjugate for selective co-delivery of two synergistic drugs docetaxel and docosahexaenoic acid to tumor cells.

Dong P, Lv H, Jia W, Liu J, Wang S, Li X Drug Deliv. 2022; 30(1):40-50.

PMID: 36458324 PMC: 9721411. DOI: 10.1080/10717544.2022.2152133.

A Novel Dextran-Based Dual Drug Conjugate Targeted Tumors with High Biodistribution Ratio of Tumors to Normal Tissues.

Liu J, Zhang N, Wu J, Dong P, Lv H, Wang Q Int J Nanomedicine. 2022; 17:4895-4910.

PMID: 36262192 PMC: 9576339. DOI: 10.2147/IJN.S379758.

Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634.

Atrafi F, van Eerden R, Koolen S, de Bruijn P, Rijcken C, Hanssen R Cancers (Basel). 2021; 13(15).

PMID: 34359641 PMC: 8345028. DOI: 10.3390/cancers13153741.

Applications of capillary action in drug delivery.

Li X, Zhao Y, Zhao C iScience. 2021; 24(7):102810.

PMID: 34296074 PMC: 8282986. DOI: 10.1016/j.isci.2021.102810.

References

Strieth S, Eichhorn M, Sauer B, Schulze B, Teifel M, Michaelis U . Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer. 2004; 110(1):117-24. DOI: 10.1002/ijc.20083. View

Atrafi F, van Eerden R, van Hylckama Vlieg M, Oomen-de Hoop E, de Bruijn P, Lolkema M . Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors. Clin Cancer Res. 2020; 26(14):3537-3545. DOI: 10.1158/1078-0432.CCR-20-0008. View

Graziani S, Vital C, Morikawa A, Van Eyll B, Fernandes Junior H, Kalil Filho R . Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma. Med Oncol. 2017; 34(9):151. DOI: 10.1007/s12032-017-1009-z. View

Mita A, Olszanski A, Walovitch R, Perez R, Mackay K, Tuck D . Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel. Clin Cancer Res. 2007; 13(11):3293-301. DOI: 10.1158/1078-0432.CCR-06-2496. View

Fetterly G, Grasela T, Sherman J, Dul J, Grahn A, Lecomte D . Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin Cancer Res. 2008; 14(18):5856-63. DOI: 10.1158/1078-0432.CCR-08-1046. View

Keam B, Lee K, Lee S, Kim J, Kim J, Wu H . A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. Oncologist. 2019; 24(6):751-e231. PMC: 6656523. DOI: 10.1634/theoncologist.2019-0070. View

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Kabanov A, Alakhov V . Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst. 2002; 19(1):1-72. DOI: 10.1615/critrevtherdrugcarriersyst.v19.i1.10. View

Fasol U, Frost A, Buchert M, Arends J, Fiedler U, Scharr D . Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. Ann Oncol. 2011; 23(4):1030-6. DOI: 10.1093/annonc/mdr300. View

10.

Mukai H, Kato K, Esaki T, Ohsumi S, Hozomi Y, Matsubara N . Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors. Invest New Drugs. 2016; 34(6):750-759. PMC: 5099351. DOI: 10.1007/s10637-016-0381-4. View

11.

Windebank A, Blexrud M, de Groen P . Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther. 1994; 268(2):1051-6. View

12.

Maeda H, Matsumura Y . Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst. 1989; 6(3):193-210. View

13.

Onoue S, Yamada S, Chan H . Nanodrugs: pharmacokinetics and safety. Int J Nanomedicine. 2014; 9:1025-37. PMC: 3934594. DOI: 10.2147/IJN.S38378. View

14.

Kim T, Kim D, Chung J, Shin S, Kim S, Heo D . Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004; 10(11):3708-16. DOI: 10.1158/1078-0432.CCR-03-0655. View

15.

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A . Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006; 12(4):1317-24. DOI: 10.1158/1078-0432.CCR-05-1634. View

16.

Rahman A, Husain S, Siddiqui J, Verma M, Agresti M, Center M . Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J Natl Cancer Inst. 1992; 84(24):1909-15. DOI: 10.1093/jnci/84.24.1909. View

17.

Hashizume H, Baluk P, Morikawa S, McLean J, Thurston G, Roberge S . Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000; 156(4):1363-80. PMC: 1876882. DOI: 10.1016/S0002-9440(10)65006-7. View

18.

Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H . A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer. 2007; 97(2):170-6. PMC: 2360299. DOI: 10.1038/sj.bjc.6603855. View

19.

Hu Q, Rijcken C, Bansal R, Hennink W, Storm G, Prakash J . Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. Biomaterials. 2015; 53:370-8. DOI: 10.1016/j.biomaterials.2015.02.085. View

20.

Maeda H, Bharate G, Daruwalla J . Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2008; 71(3):409-19. DOI: 10.1016/j.ejpb.2008.11.010. View